Aurora Urges Shareholders to Take No Action to Revised Hostile Bid by Curaleaf as Formal Review Underway

Curaleaf revised its hostile bid for all outstanding Aurora shares to implied consideration of US$5.00 per share: 0.4013 Curaleaf subordinate voting shares plus US$1.00 cash. Aurora’s Special Committee will review the bid with its advisors, and the Board will issue a formal recommendation afterward; Aurora urged shareholders to take no action in the meantime. The bid’s revised expiry date is December 4, 2026, at the earliest.

Analysis

The key exposure is deal spread and completion probability—not the stated headline value. Because consideration includes 0.4013 Curaleaf shares per Aurora share, the effective value moves with CURA; a long ACB/short CURA hedge can reduce that market risk but cannot hedge rejection, delay, or a changed offer. The cash component is fixed in US dollars, so confirm the relevant currency and share-class mechanics before sizing. Aurora’s request that holders wait is procedural, not evidence that its board will endorse the bid or that a higher offer is likely.

Near term, expect event-driven volatility around the Special Committee’s recommendation. Over the next 1–3 months, the material catalysts are the Directors’ Circular, any bid revision or extension, and evidence of shareholder support. The December expiry provides time for negotiation but also prolongs capital lock-up and exposes the spread to deal fatigue. A recommendation against the bid, weak tender indications, or a decline in CURA could sharply reduce the implied consideration. Over 6–18 months, any transaction would still need to demonstrate that integration and regulatory execution justify the strategic rationale; do not capitalize hypothetical synergies absent detail.

Contrarian point: the headline offer can anchor holders to a nominal value while obscuring the floating equity leg and execution risk. Conversely, a hostile-bid discount may overstate failure risk if the bidder remains committed. No standalone arb recommendation without live prices, bid conditions, financing details, and an assessment of approval and tender thresholds.

Key Decisions for Investors

• Event-driven desks: calculate the live spread against 0.4013 CURA shares plus US$1 cash per ACB share, then consider long ACB/short 0.4013 CURA only if the discount adequately compensates for deal-break, delay, borrow, FX, and transaction risks. No price-based entry is supportable from the supplied data.
• Keep ACB and CURA position sizing tied to the committee recommendation and subsequent bid documents; treat the formal recommendation as the next key catalyst, not Aurora’s request to take no action as a valuation signal.
• Before trading the spread, verify the bid’s conditions, any financing commitments, applicable share classes and currency treatment, CURA borrow availability/cost, and tender or shareholder-approval thresholds.
• Falsify a completion-oriented thesis on a formal board rejection without a credible path to improved terms, material adverse changes to the bid, or a CURA share-price decline that makes the revised consideration unattractive.